BLACK FRIDAY SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim→
logo
← Back to IPO overview
Himalaya Nutravedics India logo

SME IPO

Himalaya Nutravedics India IPO

ListedBSE SME

Prices in INR · Times in IST

GMP updated: 29 Sep 2026, 08:24 AM IST

Price band
₹100 – ₹106
Application estimate
₹2,54,4002 lot(s) · 1200 sh
GMP · unofficial
₹0 (0%)
Est. listing price
₹106Issue price + GMP
Issue size
₹26.5 Cr
Total subscription
2.41×

GMP trend & intraday history

29 Sep 2026
₹00%₹0 vs previous
Est. profit (2 lots · 2,400 sh)₹0
Issue price + GMP₹106
00019 Sep 2026: ₹020 Sep 2026: ₹021 Sep 2026: ₹022 Sep 2026: ₹023 Sep 2026: ₹024 Sep 2026: ₹025 Sep 2026: ₹026 Sep 2026: ₹027 Sep 2026: ₹028 Sep 2026: ₹029 Sep 2026: ₹019 Sep 202629 Sep 2026

Hover or tap on the chart to inspect a reading. Dates use calendar spacing; large gaps are not connected.

High in this view
₹0 (₹0)
Low in this view
₹0 (₹0)
Reference issue price
₹106
Readings in this view
11
Subject to sauda
0
GMP source readings
ReadingGMPPremium %Issue price + GMPEst. profit (2 lots · 2,400 sh)Subject to sauda
19 Sep 2026₹0(0%)₹106₹00
20 Sep 2026₹0(0%)₹106₹00
21 Sep 2026₹0(0%)₹106₹00
22 Sep 2026₹0(0%)₹106₹00
23 Sep 2026₹0(0%)₹106₹00
24 Sep 2026₹0(0%)₹106₹00
25 Sep 2026₹0(0%)₹106₹00
26 Sep 2026₹0(0%)₹106₹00
27 Sep 2026₹0(0%)₹106₹00
28 Sep 2026₹0(0%)₹106₹00
29 Sep 2026₹0(0%)₹106₹00

Issue at a glance

Issue Size₹26.5 Cr
Price Band₹100 – ₹106
Final Issue Price₹106
Face Value₹10
Lot Size1200 Shares
Employee Discount—
Issue TypeFresh capital only
Listing ExchangesBSE SME
NSE SymbolHNIL.BO
BSE Scrip Code7983

IPO timetable & schedule

Completed IPO lifecycleListed · 29 Sep 2026
IPO Open Date
Bidding opens
IPO Close Date
Bidding closes
Basis of Allotment
Allotment finalisation
Initiation of Refunds
Unallotted funds unblocked
Credit of Shares to Demat
Shares credited to demat
Tentative Listing Date
Exchange listing (BSE / NSE)

Subscription by investor category

Source updated: 17 Nov 2026, 04:21 PM IST

Overall Demand: 2.41×
QIB (Institutional)1×
Bid: 474000Offered: 474000
NII / HNI3.93×
Bid: 1400400Offered: 356400
Retail (Individual)2.56×
Bid: 2133600Offered: 832800
Employee0×
Bid: 0Offered: 0
Shareholder0×
Bid: 0Offered: 0
Investor categoryTimes subscribedShares offeredShares bidApplicationsDemand (₹ crore)
Qualified Institutional Buyers (QIB)1×4740004740001₹5.02 Cr
↳ Foreign Institutional Investors—04740001₹5.02 Cr
↳ Domestic Financial Institutions—00—₹0 Cr
↳ Mutual Funds—00—₹0 Cr
↳ Others—00—₹0 Cr
Non-Institutional Investors (NII)3.93×3564001400400142₹14.84 Cr
↳ bNII — bids above ₹10 Lakh4.37×237600103920046₹11.02 Cr
↳ bNII — Corporates—01260001₹1.34 Cr
↳ bNII — Individuals—090360045₹9.58 Cr
↳ bNII — Others—096001₹0.1 Cr
↳ sNII — bids ₹2 Lakh to ₹10 Lakh3.04×11880036120096₹3.83 Cr
↳ sNII — Corporates—0108003₹0.11 Cr
↳ sNII — Individuals—035040093₹3.71 Cr
↳ sNII — Others—00—₹0 Cr
Retail Individual Investors (RII)2.56×8328002133600869₹22.62 Cr
↳ Cut-off price bids—02133600889₹22.62 Cr
Employee0×00—₹0 Cr
↳ Price bids—00—₹0 Cr
Shareholder0×00—₹0 Cr
↳ Price bids—00—₹0 Cr
Total2.41×166320040080001012₹42.48 Cr

Mainboard figures are consolidated. NSE and BSE demand is not added together. Rupee demand is calculated from bid shares and the cap price; it is not an exchange-published amount. Application source: boa.

QIB funding cost illustration

Arithmetic for a fully funded institutional bid over 7 days; not a recommendation or a retail return estimate.

Days
7
Interest Rate
Not published
Cost Per Share
106

Day-wise subscription history

One snapshot near each bidding day’s close. This is not a continuous intraday series.

DayDateTime (IST)QIBNIIRetailEmployeeShareholderTotal
122 Sep 202619:00:220×0.14×0.16×0×0×0.11×
223 Sep 202619:30:480×0.49×0.67×0×0×0.44×
324 Sep 202622:02:041×3.93×2.56×0×0×2.41×

Plan your application

APPLICATION REFERENCE
Listed 29 Sep 2026
Minimum application estimate₹2,54,4002 lots · Individual applicant · At upper band

SME individual applications use 2 lots and must exceed ₹2 lakh under the NSE process effective July 2025.

The source application tiers need verification: a one-lot retail tier does not match the newer SME process. Use the rule-based estimate above and confirm the offer document.

2,400 shares × ₹106₹2,54,400

One lot: ₹1,27,200 · Allocation is not guaranteed. Broker cut-off times may differ.

Source-published application tiers
Source categoryLotsSharesAmount
Retail (Min)11200₹1,27,200
Retail (Max)11200₹1,27,200
HNI (Min)22400₹2,54,400
Before you place an IPO application
  1. Read the issue. Check the offer document, business risks, price band and your application category.
  2. Apply through your broker or bank. Use your existing broker’s IPO section or your bank’s ASBA facility. This page does not submit a bid.
  3. Check the payment step. If using UPI, confirm the mandate in your UPI app and check that the funds are blocked. A saved bid alone is not confirmation.
  4. Track what happens next. Keep your application number. Use the registrar’s official page for allotment and the published timeline for refunds, demat credit and listing.

GMP return scenario

What could this amount look like?

GMP-based scenario · Not a forecast

Application amount₹2,54,4002,400 shares
GMP-based gain / loss₹00%
Illustrative value₹2,54,400Before fees and taxes

Assumes all requested shares are allotted and listing equals issue price + GMP. Actual allotment, listing price, fees and taxes can change the result.

Your IPO progress

Keep your own record of this IPO. Statuses are entered by you, not verified with a broker or registrar. Saved on this browser for your signed-in account; not synced across devices.

IPO reservation & shares offered

Investor CategoryAllocation / Reservation
QIB11,84,400 shares (49.90% of the Offer)
NII3,56,400 shares (15.02% of the Offer)
Retail8,32,800 shares (35.09% of the Offer)

Shares offered by category

QIB Shares Offered474000
NII (HNI) Shares Offered356400
Retail Shares Offered832800

Category-wise allocation percentages follow SEBI ICDR norms as stated in the offer document.

Promoter holding & ownership

Pre-Issue Holding95.14%
Post-Issue Holding68.13%

Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsas

Anchor investors & allocations

Anchor entities
0
Total allocation (₹ crore)
0
Mutual fund allottees
0
Official allocation document
Anchor document: not published

Investor allocations

No data has been published for this section yet.

By fund house

No data has been published for this section yet.

Financials & valuation

Figures in Rs. Crore · Changes compare matching annual period-end dates only.

Profit After Tax
7.39Latest: 31 Mar 2026+231.39% YoY · Prior 2.23
EBITDA
8.1Latest: 31 Mar 2026+170.9% YoY · Prior 2.99
Total Borrowing
5.13Latest: 31 Mar 2026+191.48% YoY · Prior 1.76
Financial performance
Assets · Rs. Crore₹24.42↑+125.7%
Positive
6.09
31 Mar '24
10.82
31 Mar '25
24.42
31 Mar '26

Rs. Crore

Metric31 Mar 202631 Mar 202531 Mar 2024
Assets24.4210.826.09
Total Income43.1221.0014.43
Profit After Tax7.392.230.43
EBITDA8.102.990.94
NET Worth16.386.751.34
Reserves and Surplus10.072.760.53
Total Borrowing5.131.763.24

Key valuation & financial KPIs

P/E Ratio
12.63
EPS (₹)
8.39
RoE
63.87%
RoCE
36.41%
RoNW
45.12%
PAT Margin
17.16%
EBITDA Margin
18.82%
Debt / Equity
0.31
NAV (₹)
26.70

What does the company do?

Himalaya Nutravedics India Limited was started in June 2022. It is a Hyderabad based company that formulates, manufactures and markets Ayurvedic and nutraceutical products. Its products come in several forms, including softgel capsules, tablets, medicated oils, liquid orals, hardgel capsules and protein powders. Being able to make all of these in one place is unusual for a company of this size, because each dosage form needs its own line and approvals. Its products cover therapeutic areas such as digestive health, immunity, metabolic health and pain management. It sells in two ways. Its own branded products are marketed through healthcare practitioners rather than through mass advertising, so doctors recommending the product is what drives sales. Alongside that it manufactures on a third party contract basis for other brands. It has expanded to 17 states and one union territory in India. Its manufacturing facility is in Hyderabad, Telangana and holds ISO 22000:2018, ISO 9001:2015 and WHO-GMP certification. As on 30 April 2026 it had 80 employees.

More about the business

Himalaya Nutravedics India Limited is a Hyderabad-based Ayurvedic and nutraceutical manufacturer making softgel capsules, tablets, medicated oils, liquid orals and protein powders across digestive, immunity, metabolic and pain management categories. It sells through healthcare practitioners and also does third-party contract manufacturing across 17 states.

Where will the money go?

Use of proceedsAmount (₹ crore)
Funding Working Capital Requirements13.75
Business Development and Digital Marketing Activities7.5
General Corporate Purposes—

Strengths & risks

Business strengths

  • Sales have tripled in two years, from Rs 14.43 crore in FY2024 to Rs 21.00 crore in FY2025 and Rs 43.12 crore in FY2026.
  • Profit has grown from Rs 0.43 crore in FY2024 to Rs 2.23 crore in FY2025 and Rs 7.39 crore in FY2026.
  • The margin is high for a small manufacturer, with a PAT margin of 17.16% and an EBITDA margin of 18.82%.
  • Return ratios are very strong, with RoNW of 45.12% and RoCE of 36.41%.
  • Debt is low. Total borrowing was Rs 5.13 crore against a net worth of Rs 16.38 crore, a debt to equity ratio of only 0.31.
  • The issue is priced at about 12.63 times earnings on an EPS of Rs 8.39.
  • It can make several dosage forms in one facility, from softgels and tablets to oils, liquids and powders, which lets it serve a wider set of contract manufacturing customers.
  • The Hyderabad facility holds WHO-GMP certification along with ISO 22000:2018 and ISO 9001:2015, which matters for both export and contract work.

Risks to understand

  • The company is very young. It was started only in June 2022, so it has around four years of history and has not been tested through a difficult period.
  • The growth is from a very small base. Sales tripled and profit rose about seventeen times in two years, which cannot be assumed to continue.
  • Rs 7.50 crore of the Rs 26.5 crore issue goes into business development and digital marketing. That is a running cost rather than an asset, and it will need to be spent again.
  • Sales depend on healthcare practitioners recommending the products. That relationship has to be maintained continuously and can be won away by competitors.
  • The whole business runs from one facility in Hyderabad, so there is single location risk.
  • Ayurvedic and nutraceutical products are a crowded category with low barriers to entry and many small manufacturers.
  • The contract manufacturing part of the business earns a lower margin than selling its own brands.
  • Promoter holding will come down from 95.14% to 68.13% after the issue.
  • This is an SME issue. One lot is 1,200 shares, which is about Rs 1.27 lakh at the upper band of Rs 106, and SME shares usually trade in low volume after listing.

Source-provided company information. Read the RHP for the complete risk factors; these points are not a recommendation.

Listing performance

Listing price₹118
Listing day gain+11.32%
Current market price₹165
Current gain vs IPO+55.66%

Actual listing figures appear after listing. Current gain is source-adjusted for corporate actions. CMP is a source snapshot, not a streaming quote.

Official documents, registrar & contacts

Offer documents

Red Herring Prospectus (RHP)
Read RHP: not published
Draft Prospectus (DRHP)
Read DRHP: not published
Anchor Allocation
Read Anchor Doc: not published
Basis of Allotment
Registrar & Allotment

KFin Technologies Limited

Phone: 040-79615565

Email: himalaya.ipo@kfintech.com

Allotment date: 25 Sep 2026

Book Running Lead Managers
  • •Nirbhay Capital Services
Company Registered Office

Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad, Telangana, 500051

Phone: +91-9063498493

Email: info@himalayanutravedics.com

Continue your IPO research

Explore more IPO companies

Related by issue type, with active issues first. These are research links, not investment recommendations.

IPO data by StockeZee · Prices in INR · Times in IST

GMP is an unofficial, unregulated market signal. Issue price + GMP is an arithmetic reference, not a listing forecast or assured return. Subscription does not guarantee allotment. Read the offer documents and company risks before investing.